⚠ The Curse of SizeModerate threat
Berkshire Hathaway (BRK.B) — threat to the moat
At a trillion dollars, only elephants move the needle — and the bargains that built the record are too small to matter now.
Berkshire's very success has created a subtler problem that no amount of skill can entirely solve: it has grown so enormous that the opportunities capable of moving the needle have become scarce. When a company is small, a single brilliant investment can transform its fortunes; when it is one of the largest enterprises on earth, awash in cash, only the biggest acquisitions and stakes are large enough to matter, and there are only so many of those, rarely available at attractive prices. Size is the enemy of the outsized returns that built the reputation.
The danger is not of loss but of mediocrity — of a great compounding machine slowing to the pace of the overall economy simply because it can no longer find enough bargains big enough to matter. The cash piles up faster than genuinely attractive opportunities appear, which forces a hard choice between sitting on low-returning cash, overpaying for the few large deals available, or returning capital to shareholders — an admission that the company can no longer reinvest at the rates that made it famous.
There are real consolations, however. Berkshire's scale is itself a moat in certain deals — it can write checks and absorb risks almost no one else can, which makes it the only possible buyer for some very large businesses and the insurer of last resort for the largest catastrophes. Share buybacks offer a sensible outlet for excess cash when nothing better appears, quietly increasing each remaining owner's slice. And a business that compounds at a steady, unspectacular rate on an enormous base is still creating vast amounts of value in absolute terms.
A long-term owner should simply calibrate expectations rather than worry about the moat, which size does not weaken at all — it merely caps the upside. The decades of spectacular returns are almost certainly behind the company, not because anything has gone wrong but because arithmetic is unforgiving at scale. The prudent view is to admire Berkshire as a durable, fortress-like compounder that will likely grow steadily and safely, while recognizing that the era when it could double and redouble is a function of a smaller past that will not return — OxyChem, the largest deal in four years at about $9.4 billion, used less than 3% of $365.5 billion of cash and Treasury bills at the end of June 2026.12
At this size only deals of $10B or more move earnings: OxyChem added about 2%. A decade of operating earnings growing below 5% a year would confirm the curse.
- ReportedThe prudent view is to admire Berkshire as a durable, fortress-like compounder that will likely grow steadily and safely, while recognizing that the era when it could double and redouble is a function of a smaller past that will not return — OxyChem, the largest deal in four years at about $9.4 billion, used less than 3% of $365.5 billion of cash and Treasury bills at the end of June 2026.Berkshire Hathaway Form 10-Q, quarter ended 30 June 2026 - after-tax earnings (underwriting $1,731M vs $1,992M, insurance investment income $3,059M vs $3,367M, BNSF $1,558M vs $1,466M, BHE $891M vs $702M, manufacturing, service and retailing $4,470M vs $3,601M, investment gains $12,684M, net earnings $25,667M); GEICO pre-tax underwriting $994M vs $1,821M, combined ratio 91.2% vs 83.5%; Reinsurance $913M vs $650M; float $177.5B; insurance and other cash and Treasury Bills net $359.2B; consolidated cash $35,096M + $324,905M + $5,513M; equity securities $323.8B; H1 purchases of equities $39.4B and sales $27.8B; acquisitions of businesses net of cash $9.7B; $4.8B of treasury stock acquired in H1, most in Q2; OxyChem about $9.4B on 2 January; Taylor Morrison agreed 31 May at $72.50 a share, about $6.8B, closed 24 July; notes payable of insurance and other $43.3B; shareholders' equity $747.9B; BNSF revenue $6,601M vs $5,769M, fuel $1,173M vs $698M; BHE revenue $6,735M vs $6,418M; investment income down 9.1% on lower interest rates — Q2 2026 · publ. August 2026 · source ↗
- Moat Explorer calcThe prudent view is to admire Berkshire as a durable, fortress-like compounder that will likely grow steadily and safely, while recognizing that the era when it could double and redouble is a function of a smaller past that will not return — OxyChem, the largest deal in four years at about $9.4 billion, used less than 3% of $365.5 billion of cash and Treasury bills at the end of June 2026.Moat Explorer calculation from Berkshire's Forms 10-K FY2016-FY2025 and 10-Qs for Q1 and Q2 2026: operating earnings = net earnings less after-tax investment gains and the 2025 impairments (FY2023 $37,350M, FY2024 $47,437M, FY2025 $44,486M; Q2 2026 $12,983M vs $11,160M; H1 2026 $24,329M vs $20,801M); consolidated cash and Treasury Bills $397.4B (31 March 2026) and $365.5B (30 June 2026); underwriting as a share of float; OxyChem at 2.6% of the cash pile; five-line after-tax earnings sums — 2016 to Q2 2026 · publ. 2026-09-23 · source ↗
- Berkshire Hathaway Form 10-K filings — Business & Risk Factors (SEC EDGAR)
- Berkshire Hathaway 2024 shareholder letter (berkshirehathaway.com)
- Berkshire Hathaway financials, FY2021–FY2025 (stockanalysis.com)